TMO Fairly Valued by DCF at $478
On May 26, 2026, we present a DCF analysis for Thermo Fisher Scientific Inc (TMO). The stock has experienced a mixed performance recently, with a year-to-date d
TMO - Thermo Fisher Scientific Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$638.20
DETAILS
HIGH:
$750.00
LOW:
$490.00
MEDIAN:
$644.50
CONSENSUS:
$638.20
UPSIDE:
42.40%
Stock News
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
Thermo Fisher Scientific Announces Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier.
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company's industry leadership and the essential role of its best-in-class products and services to customers around the world. "Our customers value Thermo Fisher as their trusted partner,” said Marc N. Casper, chairman and chief executive office.
Amazon, McDonald Surge Into Jefferies Top Picks Broadcom as Gets Cut
Jefferies refreshed its Franchise Picks list, adding Amazon (AMZN), AppLovin (APP), Credo Technology (CRDO), McDonald's (MCD), RadNet (RDNT), and Thermo Fisher
Jefferies updates its list of highest-conviction Buy-rated stocks
Jefferies, an investment banking and capital management firm, has updated its ‘Franchise Picks' list, which features the company's highest-conviction ‘Buy' rated stocks.
Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company's global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the la.
Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle
ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sacrificing the simplicity, durability, and approachable price points they expect from a Nalgene bottle. The result is a slim 24-oz bottle paired with a new interchangeable Fresh Flow cap that lets fans sip from a straw, chug from a spout, or swap the cap onto other Nalgene bottles they already own. T.
TMO DCF Analysis: Intrinsic Value $478 vs Price $465
On May 11, 2026, we present a discounted cash flow (DCF) analysis for Thermo Fisher Scientific Inc (TMO). The company has experienced a challenging price perfor
Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company's continued investment in digital innovation across the clinical development continuum. The recognition highlights the strength of Thermo Fisher's PPD™ clinical research business, which is recognized for its capabilities in clinic.
International Markets and Thermo Fisher (TMO): A Deep Dive for Investors
Examine Thermo Fisher's (TMO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to s.
TMO Fairly Valued by DCF at $478
On May 04, 2026, we present a detailed DCF analysis for Thermo Fisher Scientific Inc (TMO), a company that has experienced a price decline of 18.9% year-to-date
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company's Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faste.
Thermo Fisher Scientific to Host Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in New York City. The format will feature presentations by members of Thermo Fisher Scientific's senior management team and conclude with a Q&A session. The live webcast of the presentation can be accessed via the Investors section of our website, https://ir.thermofisher.com. A replay of the webc.
Thermo Fisher to Sell Microbiology Business to Astorg
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion
Thermo Fisher Scientific said on Monday it has agreed to sell its microbiology business to a pan-European private equity firm Astorg for about $1.08 billion, consisting of cash and a $50 million seller note.
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food.
TMO Fairly Valued by DCF at $478
On April 27, 2026, we delve into the DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently facing a challenging price performance with a year
Comerica Bank Cuts Position in Thermo Fisher Scientific Inc. $TMO
Comerica Bank lessened its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 4.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,308 shares of the medical research company's stock after selling 3,787 shares during the period.
Price Targets
Thermo Fisher resumed with a Sector Perform at RBC Capital
$490.00
(was $448.21)
RBC Capital
Thermo Fisher price target lowered to $620 from $670 at Morgan Stanley
$620.00
(was $472.23)
Kallum Titchmarsh
·
Morgan Stanley
Thermo Fisher price target lowered to $600 from $700 at Stifel
$600.00
(was $467.47)
Daniel Arias
·
Stifel Nicolaus
Thermo Fisher price target lowered to $639 from $653 at Baird
$639.00
(was $466.70)
Catherine Ramsey Schulte
·
Robert W. Baird
Thermo Fisher price target raised to $615 from $590 at UBS
$615.00
(was $579.86)
UBS
Thermo Fisher Scientific (TMO) PT Lowered to $683 at TD Cowen
$683.00
(was $580.09)
Wells Fargo
Thermo Fisher price target raised to $653 from $645 at Baird
$653.00
(was $583.12)
Robert W. Baird
Thermo Fisher price target raised to $650 from $625 at Barclays
$650.00
(was $592.16)
Barclays
Thermo Fisher price target raised to $700 from $583 at Stifel
$700.00
(was $606.50)
Daniel Arias
·
Stifel Nicolaus
Thermo Fisher price target raised to $650 from $610 at Evercore ISI
$650.00
(was $605.83)
Vijay Kumar
·
Evercore ISI
Thermo Fisher price target raised to $675 from $635 at Wells Fargo
$675.00
(was $571.99)
Wells Fargo
Thermo Fisher initiated with a Buy at Goldman Sachs
$685.00
(was $568.21)
Evie Koslosky
·
Goldman Sachs
Thermo Fisher upgraded to Overweight from Sector Weight at KeyBanc
$750.00
(was $572.77)
Paul Knight
·
KeyBanc
Thermo Fisher price target raised to $610 from $580 at Argus
$610.00
(was $570.82)
Argus Research
Thermo Fisher price target raised to $656 from $560 at Morgan Stanley
$656.00
(was $563.28)
Morgan Stanley
Thermo Fisher price target raised to $590 from $500 at UBS
$590.00
(was $571.67)
UBS
Thermo Fisher price target raised to $625 from $585 at Barclays
$625.00
(was $567.20)
Barclays
Thermo Fisher price target raised to $580 from $545 at Leerink
$580.00
(was $567.20)
Leerink Partners
Thermo Fisher price target raised to $575 from $525 at Rothschild & Co Redburn
$575.00
(was $536.19)
Redburn Partners
Thermo Fisher price target raised to $580 from $525 at Rothschild & Co Redburn
$580.00
(was $539.17)
Redburn Partners